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Background. Neuroimaging studies have demonstrated an association between lithium (Li) treatment and brain struc-
ture in human subjects. A crucial unresolved question is whether this association reflects direct neurochemical effects of
Li or indirect effects secondary to treatment or prevention of episodes of bipolar disorder (BD).
Method. To address this knowledge gap, we compared manually traced hippocampal volumes in 37 BD patients with at
least 2 years of Li treatment (Li group), 19 BD patients with <3 months of lifetime Li exposure over 2 years ago (non-Li
group) and 50 healthy controls. All BD participants were followed prospectively and had at least 10 years of illness and a
minimum of five episodes. We established illness course and long-term treatment response to Li using National Institute
of Mental Health (NIMH) life charts.
Results. The non-Li group had smaller hippocampal volumes than the controls or the Li group (F2,102=4.97, p=0.009).
However, the time spent in a mood episode on the current mood stabilizer was more than three times longer in the Li
than in the non-Li group (t51=2.00, p=0.05). Even Li-treated patients with BD episodes while on Li had hippocampal
volumes comparable to healthy controls and significantly larger than non-Li patients (t43=2.62, corrected p=0.02).
Conclusions. Our findings support the neuroprotective effects of Li. The association between Li treatment and hippo-
campal volume seems to be independent of long-term treatment response and occurred even in subjects with episodes of
BD while on Li. Consequently, these effects of Li on brain structure may generalize to patients with neuropsychiatric
illnesses other than BD.
Received 11 January 2013; Revised 18 April 2013; Accepted 30 April 2013; First published online 31 May 2013
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Introduction
Neuroprotective effects of lithium (Li) have been docu-
mented in tissue cultures and animal models (Gould
et al. 2006; Zarate et al. 2006). Prospective and cross-
sectional neuroimaging studies in human subjects
have shown an association between Li treatment and
larger gray matter (GM) volumes (Moore et al. 2000,
2009; Monkul et al. 2007; Yucel et al. 2007; Lyoo et al.
2010; Hajek et al. 2012c). However, the nature and
mechanism of these in vivo actions of Li remain unclear
(Bauer et al. 2003). Without further clinical research, the
potential neuroprotective effects of Li are of little prac-
tical benefit to our patients.
For example, we do not know whether the positive
association between GM volumes and Li treatment
reflects a direct neurochemical effect of Li or an indirect
effect secondary to treatment response (Moore et al.
2009; Lyoo et al. 2010). Li could exert neurotrophic
effects by interacting with biochemical pathways
involved in neurogenesis and apoptosis (Zarate et al.
2006). Alternatively, Li may affect brain structure
through treatment or prevention of episodes of bipolar
disorder (BD), which are known to exert toxic effects
* Address for correspondence: T. Hajek, M.D., Ph.D., Department of
Psychiatry, Dalhousie University, QEII HSC, Abbie J. Lane Bldg,
Room 3093, 5909 Veteran’s Memorial Lane, Halifax, NS B3H 2E2,
Canada.
(Email: tomas.hajek@dal.ca)
Psychological Medicine (2014), 44, 507–517. © Cambridge University Press 2013
doi:10.1017/S0033291713001165
ORIGINAL ARTICLE
https://doi.org/10.1017/S0033291713001165
Downloaded from https://www.cambridge.org/core. SLUB Dresden, on 03 Feb 2020 at 09:30:13, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
on the brain (Berk et al. 2011; Hajek et al. 2012a). This
distinction is crucial. If the effects of Li on brain struc-
ture were simply related to acute or prophylactic treat-
ment response, they would probably not generalize
to other conditions, such as Alzheimer’s disease
(AD). Prospective short-term studies have shown that
GM increases mostly in patients who also improve
clinically (Lyoo et al. 2010) or even predominantly
among responders to acute treatment (Moore et al.
2009). This might indicate that the GM changes are
an epiphenomenon of treatment response rather than
a direct result of Li exposure. However, no study has
investigated the association between brain structure
and long-term prophylactic response to Li.
In addition, the GM differences between patients
with versus without Li treatment may reflect patient
heterogeneity rather than effects of Li (Hajek et al.
2012c). The Li responders are likely to represent a dis-
tinct neurobiological category within BD (Grof et al.
2009). It is possible that it is only the patients who
do not respond to Li who have a neuroprogressive
nature of the illness and show brain structural
changes. It would be of much less practical impact if
the association between Li treatment and GM volumes
simply reflected neurobiological differences between
Li responders and non-responders rather than the
effects of Li.
We addressed the above-listed issues in a sample
of prospectively followed patients with BD and
either long-term ongoing Li treatment (minimum of
2 years) or no/minimal lifetime Li exposure. To maxi-
mize the effects of BD on the brain, we recruited BD
patients with substantial illness burden (minimum of
10 years of illness and at least five episodes). Among
brain regions, Li treatment has been associated most
consistently with hippocampal volume increases even
at meta- (Hajek et al. 2012c) and mega-analytical
(Hallahan et al. 2011) levels. Therefore, we chose the
hippocampus as our model region to further investi-
gate the interplay between treatment response and
potential neuroprotective effects of Li. Our a priori
hypothesis was that hippocampal volumes would be
smaller among BD patients with substantial illness
burden and limited Li exposure, whereas BD patients
with substantial illness burden and ongoing Li treat-
ment would show comparable hippocampal volumes
to controls. We also hypothesized that the positive
effects of Li on hippocampal volumes would be
found only among subjects with no episodes of BD
while being treated with Li.
Method
This study was designed specifically to test the effects
of long-term Li exposure on hippocampal volumes.
Through recruitment of patients with substantial
illness burden (duration of illness, number of epi-
sodes), we attempted to maximize the effect of BD
on the brain (Moorhead et al. 2007; McKinnon et al.
2009). By setting stringent criteria for presence and
also absence of Li treatment, we ensured a sufficient
contrast between the groups in exposure to Li and
minimized any effect of past history of Li treatment
on GM volumes. Patients were not required to show
complete treatment response to Li. They may have
had a partial response, Li could have been effective
in treating but not preventing the symptoms or may
have prevented or effectively treated only episodes of
one polarity. Li may have also been used for antisuici-
dal effects or as an augmentation. This allowed us to
investigate whether we would detect the association
between Li treatment and brain structure even in
patients who continued to experience episodes of BD
while on Li, or whether these effects required cessation
of episodes.
We studied three groups of subjects: (1) those
with substantial ongoing exposure to Li and a marked
illness burden (Li group), (2) those with limited or no
lifetime exposure to Li and a marked illness burden
(non-Li group) and (3) an age- and sex-matched con-
trol group. To test whether the association between
Li treatment and brain structure was present despite
ongoing episodes of illness, we divided the Li-treated
subjects based on whether they did or did not experi-
ence a major depressive, mixed or manic episode
according to the full DSM-IV criteria while being trea-
ted with Li. The episode had to be of at least moderate
severity according to the life-chart method (Roy-Byrne
et al. 1985), which corresponds to an affective mor-
bidity index of at least 2, that is change in symptoms
requiring an intervention (Coppen et al. 1976).
The International Group for the Study of Lithium-
Treated Patients (IGSLi; www.igsli.org) conducted
the study. Participants were recruited in Halifax,
Canada (n=33), Poznan, Poland (n=20), Neunkirchen,
Austria (n=21), and Dresden (n=5) and Berlin,
Germany (n=27).
The study was approved by the Research Ethics
Boards at each site. After complete description of
the study, all included subjects signed an informed
consent. Of the 106 subjects recruited for this study,
47 had also participated in our previous investigation
of prefrontal N-acetylaspartate (Hajek et al. 2012a).
Settings
Patients with BD were recruited from specialized
mood disorders clinics at each site. All patients were
diagnosed by psychiatrists using the Structured
Clinical Interview for DSM-IV (SCID) and had regular
508 T. Hajek et al.
https://doi.org/10.1017/S0033291713001165
Downloaded from https://www.cambridge.org/core. SLUB Dresden, on 03 Feb 2020 at 09:30:13, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
follow-up at the clinics, including monitoring of
Li levels at least twice a year. Recruitment of
Li-treated subjects from specialized clinics ensured
that Li levels fell in the therapeutic range. This pre-
vented subtherapeutic levels, which could be insuffi-
cient to elicit neuroprotective effects, and levels
above the therapeutic range, which could be neuro-
toxic. We established illness course and treatment
response to Li using the National Institute of Mental
Health Life-Chart Method (NIMH-LCM™; Roy-Byrne
et al. 1985). We also recruited control subjects, by
word of mouth and through advertisement, who were
matched to the BD patients by age and sex. Each
control subject underwent a SCID and was included
if found to have no personal or family history of
Axis I psychiatric disorders.
Inclusion criteria
The BD participants (both Li and non-Li groups)
were required to have: (1) the diagnosis of BD type I
or II made by a psychiatrist using the SCID; (2)
at least 10 years duration of illness; (3) a history of
at least five major affective episodes (hypomanic,
manic, depressive or mixed); and (4) absence of
major mood episode based on DSM-IV criteria during
prospective follow-ups at least 4 months before
recruitment, to minimize confounding by state-related
factors.
The Li-treated group (Li group) had to have a
current adequate Li treatment lasting a minimum of
24 months. Adequate Li treatment was defined as
plasma levels between 0.5 and 1.2 mmol/l on every
blood test, with a frequency of blood tests minimally
twice every 12 months (Licht et al. 2003). The group
of patients with no or minimal exposure to Li (non-Li
group) had to have less than 3 months of lifetime
Li exposure, and no Li for at least 24 months prior to
scanning.
Exclusion criteria
Subjects from any of the three groups were excluded
if they met any magnetic resonance imaging (MRI)
exclusion criteria or had any serious medical illness
(e.g. brain injury, Cushing’s disease or conditions
treated with corticosteroids).
BD patients were excluded if they had (1) more
than one lifetime course of electroconvulsive therapy
(ECT); (2) co-morbid Axis I or II psychiatric disorders;
(3) active substance abuse in the previous 12 months;
(4) discontinuation or introduction of a psychotropic
medication in the past 3 months; (5) more than two
psychotropic medications excluding benzodiazepines
or hypnotics; or (6) current psychotic features or acute
suicidality.
MRI acquisitions
InHalifax,MRacquisitionswere performedwith a 1.5-T
General Electric Signa scanner (General ElectricMedical
Systems, USA) and a standard quadrature head coil.
After a localizer scan, a T1-weighted spoiled gradient
recalled (SPGR) scan was prescribed with the following
parameters: flip angle=40°, echo time (TE)=5ms, rep-
etition time (TR)=25ms, matrix=256×160 pixels, num-
ber of excitations (NEX)=1, no inter-slice gap, 124
images, 1.5 mm thick.
In Dresden, MR acquisitions were performed with a
1.5-T Siemens, Sonata scanner (Siemens AG, Germany)
and a standard quadrature head coil. After a local-
izer scan, a T1-weighted three-dimensional (3D)
magnetization-prepared rapidacquisitionwith gradient
echo (MPRAGE) scanwasprescribedwith the following
parameters: flip angle=15°, TE=3.93ms, TR=2280ms,
matrix=256×256 pixels, NEX=1, no interslice gap, 160
images, 1.0mm thick.
In Poznan, MR acquisitions were performed with
a 1-T General Electric Signa scanner and a standard
quadrature head coil. After a localizer scan, a T1-
weighted SPGR scan was prescribed with the follow-
ing parameters: flip angle=45°, TE=6ms, TR=22ms,
matrix=256×256 pixels, NEX=1, no interslice gap, 124
images, 1.2 mm thick.
In Neunkirchen, MR acquisitions were performed
with a 1-T Siemens, Magnetom Expert scanner and a
standard quadrature head coil. After a localizer scan,
a T1-weighted 3D MPRAGE scan was prescribed
with the following parameters: flip angle=15 degrees,
TE=4.4 ms, TR=1.1, matrix=256×256 pixels, NEX=1,
no interslice gap, 112 images, 1.5 mm thick.
In Berlin, MR acquisitions were performed with
a 1.5-T Siemens scanner and a standard quadrature
head coil. After a localizer scan, a T1-weighted 3D
MPRAGE scan was prescribed with the following
parameters: flip angle=15°, TE=3.93ms, TR=2280ms,
matrix=256×256 pixels, NEX=1, no interslice gap,
160 images, 1 mm thick. The acquisition parameters
reflected the expertise and previous experience of radi-
ologists within each site, who preferred to use methods
with which they were already familiar and that yielded
high quality data on their individual scanners.
Hippocampus measurement
We used manual tracing to measure hippocampal
volumes. Relative to primarily exploratory voxel-based
morphometry (VBM), manual volumetry was more
optimal for our hypothesis testing study, allowing for
a better control of differences between the sites (see
Statistical analyses) and a greater statistical power.
VBM, even with small volume correction, requires
control for hundreds of voxelwise comparisons within
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the masks constituting the hippocampus. In addition,
manual volumetry has been used more widely in pre-
vious studies investigating the effects of Li on brain
structure (Hajek et al. 2012c), thus allowing for a better
comparability of results with previous investigations.
We analyzed the data with the AFNI software
package (NIMH, USA; http://afni.nimh.nih.gov/afni/).
In addition to the T1-weighted images, we used the
AFNI swap feature to generate negatives that ap-
proximated a T2-weighted image. This allowed a better
visualization of the alveus.
A single rater (K.Y.) blind to diagnostic status and
Li treatment history measured the right and left hippo-
campi using a manual tracing method with an estab-
lished protocol (Yucel et al. 2008). The hippocampus
was defined anatomically as the hippocampus proper
(Ammon’s horn), the dentate gyrus and the subiculum.
The alveus, fimbria and fornix were excluded from
these measurements. Hippocampal volumes were
measured by one rater with reliability confirmed by a
second investigator, falling within 5% between raters.
The intraclass correlation coefficient for reliability of
hippocampal tracings was 0.97 and 0.99 for the right
and left hippocampus respectively.
Statistical analyses
We compared categorical clinical and demographic
variables using Pearson’s χ2 test and continuous vari-
ables using a one-way analysis of variance (ANOVA)
or the t test. The primary analysis for the neuroimaging
data was a repeated-measures analysis of covariance
(ANCOVA) with hippocampal volumes as the depen-
dent variable, side (left, right) as the repeated measure,
group (Li, non-Li, control) as the categorical factor and
total GM as a covariate. Covarying for GM controlled
for global effects of Li and adjusted for potential differ-
ences between the sites. Because the duration of illness
was truncated by our inclusion criteria and there was
no association between duration of illness and hippo-
campal volumes, we did not use it as another covari-
ate. We also compared each two of the three groups
with post-hoc pairwise t tests, for which we report
p values corrected for three comparisons. As there
was no interaction between side and group, we used
total hippocampal volumes adjusted for total GM in
post-hoc analyses.
To further control for potential differences between
the sites, we (1) calculated z scores within each site
and used these for the analyses, and (2) used the
raw data and performed repeated-measures ANOVA
with hippocampal volumes as the dependent variable,
side (left, right) as the repeated measure and status
(Li, non-Li, control subjects) and group as the categori-
cal factors. This last method was used for sites that
contributed sufficient numbers of participants in each
group, namely Halifax, Neunkirchen and Poznan. No
non-Li participants were recruited in Berlin, and the
Dresden site recruited a total of five subjects.
To test whether the effects of Li on hippocampal
volumes were related to treatment response, we com-
pared patients with episodes while on Li to patients
with no episodes on Li, controls and the non-Li
group in a series of t tests. We corrected the p values
for three comparisons. As there was no interaction
between side and group for any of the previous ana-
lyses, we used total hippocampal volumes adjusted
for total GM as the dependent variable. To investigate
the association between clinical measures and hippo-
campal volumes, we calculated product-moment cor-
relation coefficients.
Results
We recruited 19 non-Li, 37 Li-treated BD patients and
50 controls (Table 1). Both patient groups (Li and
non-Li) had a marked burden of illness, with no sig-
nificant differences between the Li and the non-Li
groups in numbers of episodes, cumulative time
spent in episodes, or age of onset (Table 2). The time
spent in a mood episode while on the current mood
stabilizer, the duration of the last episode and the
overall duration of illness (time since the first episode)
were longer in the Li than the non-Li group (Table 2).
Non-Li participants were predominantly treated
with anticonvulsants and antipsychotics. One of the
BD patients in the non-Li group had had lifetime
exposure to Li 9 years prior to the scanning, but did
not reach therapeutic levels at that time. The rest of
the non-Li group were Li naïve. The duration of Li
treatment in the Li group was 10.81±7.82 years, with
Li levels of 0.70±0.16mmol/l at the time of scanning.
There were no differences between the groups in the
volumes of the whole brain, GM, white matter or
cerebrospinal fluid (CSF) (Table 1).
Hippocampal volumes
As shown in Fig. 1 and Table 1, we found significant
differences between the groups in hippocampal
volumes (F2,102=4.97, p=0.009). This difference was
caused by significantly smaller hippocampal volumes
among the non-Li group relative to controls (t67 =
−3.06, corrected p=0.005) and also relative to the
Li-treated BD participants (t54=−2.66, corrected p=0.02).
The pattern of the smallest hippocampal volumes
in the non-Li group was found in each of the sites.
The Li-treated participants had comparable hippo-
campal volumes to control subjects. The right hippo-
campus was significantly larger than the left
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hippocampus (F1,103=32.07, p<0.001) in all groups
(no interaction between the group and side; F2,103=
2.28, p=N.S.).
The group differences remained significant when
we used z scores instead of raw hippocampal
volumes (F2,103=3.82, p=0.02) or when we included
site as another factor (main effect of group: F2,65=
4.94, p=0.01). There were no differences between
the sites in the pattern of findings, as indicated by
no interaction between the site and group (F4,65 =
1.96, p=N.S.).
Li-treated patients who continued to experience
episodes of illness while on Li (n=25) had larger
hippocampal volumes than participants in the
non-Li group (t42=2.62, corrected p=0.02) and did
not differ from controls (t73 =–0.13, p=N.S.) or the
Li-treated patients with no episodes while on Li
(n=12; t36=0.43, p=N.S.) (see Fig. 2).
Hippocampal volumes did not correlate sig-
nificantly with any of the clinical measures listed in
Table 2 in either the Li or the non-Li group. When
we excluded patients treated with anticonvulsants
or antipsychotics, there continued to be the same
pattern of significant differences between the groups,
caused by the smallest hippocampal volumes among
the non-Li participants (F2,85=4.32, p=0.02 and F2,92 =
3.18, p<0.05 respectively).
Discussion
Among BD participants with substantial illness bur-
den, the group with no or limited lifetime exposure
to Li had smaller hippocampal volumes than the
Li-treated BD participants, who had hippocampal
volumes comparable to controls. This was despite a
higher activity of illness on the current mood stabil-
izer in the Li than the non-Li group, suggesting that
the effects of Li on hippocampal volumes were un-
related to the long-term treatment response. Indeed,
participants who continued to experience episodes
of BD while being treated with Li had comparable
hippocampal volumes to those with no episodes
while on Li or controls and larger hippocampal
volumes than patients not treated with Li. Con-
sequently, because the effects of Li on hippocampal
volumes seemed to be independent of its effects on
episodes of BD, they might not be restricted to
those with mood disorders.
Our findings are in keeping with other studies that
have reported smaller hippocampal volumes in BD
patients not treated with Li relative to controls or
Li-treated participants (Hajek et al. 2012c). One possi-
bility is that the preserved hippocampal volumes
in Li-treated subjects do not reflect the effects of Li,
but rather the neurobiological differences betweenTa
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Li responders and non-responders. Treatment re-
sponse to Li was not a selection criterion in this
study and 69% of patients continued to experience epi-
sodes of illness while on Li. In addition, all but one of
the non-Li participants were Li naive and there could
have been Li responders among them. Consequently,
potential neurobiological differences between Li
responders and non-responders were highly unlikely
to explain the results. A more parsimonious interpret-
ation is that the observed differences were related
to differential exposure to Li rather than to patient
heterogeneity. Indeed, prospective studies have also
suggested a causal association between Li exposure
and brain structure, by showing GM increases pre-
versus post-Li treatment (Moore et al. 2000, 2009;
Monkul et al. 2007; Yucel et al. 2007) and, even more
importantly, by demonstrating a greater GM change
over time following randomly assigned treatment
with Li compared with treatment with valproate or
no treatment (Lyoo et al. 2010).
This is the first study to investigate the inter-
play between the long-term, prophylactic response to
Li (i.e. prevention of episodes) and brain structural
changes. Contrary to our findings, some previous pro-
spective investigations reported a positive association
between acute treatment response (i.e. symptom re-
duction) and brain structure (Moore et al. 2009; Lyoo
et al. 2010). This difference may be related to the fact
that symptom reduction and episode prevention are
clinically and neurobiologically distinct outcomes
(Lenox & Hahn, 2000; Machado-Vieira et al. 2009;
Willner et al. 2012). In addition, the previous studies
investigated subjects after 4 weeks of Li treatment
(Moore et al. 2009; Lyoo et al. 2010), as opposed to a
minimum of 2 years and an average of 10.8 years in
this study. It is possible that an acute treatment
Table 2. Comparison of clinical variables between the non-Li and Li groups
Non-Li (n=19) Li (n=37) t; df or χ2; df p
Lifetime manic episodes, n (S.D.) 1.63 (1.54) 2.35 (2.73) −1.06; 54 0.29
Cumulative duration of manic episodes (months), mean (S.D.) 4.37 (6.68) 6.26 (7.34) −0.94; 53 0.35
Lifetime depressive episodes, n (S.D.) 6.16 (5.59) 5.81 (5.71) 0.22; 54 0.83
Cumulative duration of depressive episodes (months), mean (S.D.) 16.92 (10.69) 24.99 (30.59) −1.11; 52 0.27
Duration of untreated illness (years), mean (S.D.) 7.33 (8.4) 7.84 (10.36) −0.19; 54 0.85
Duration of illness (years), mean (S.D.) 19.44 (10.86) 25.47 (9.4) −2.16; 54 0.04
Lifetime episodes overall, n (S.D.) 7.79 (5.36) 8.16 (6.01) −0.23; 54 0.82
Number of episodes while on Li (Li group) or the latest mood
stabilizer (non-Li group), n (S.D.)
1.56 (2.63) 1.97 (2.69) −0.51; 51 0.61
Time spent in mood episode while on Li (Li group) or the
latest mood stabilizer (non-Li group) (months), mean (S.D.)
2.44 (4.80) 9.55 (13.79) −2.00; 51 0.05
Time since the last episode (years), mean (S.D.) 4.51 (6.42) 5.89 (5.05) −0.88; 54 0.38
Depression as the last episode, n (%) the rest mania/hypomania
or mixed
9 (47.37) 24 (64.86) 1.62; 2 0.44
Duration of the last episode (months), mean (S.D.) 2.47 (1.93) 6.42 (7.64) −2.2; 54 0.03
Li level (mmol/l), mean (S.D.) N.A. 0.7 (0.16) N.A. N.A.
Li treatment duration at the time of scanning (years), mean (S.D.) N.A. 10.81 (7.82) N.A. N.A.
Latency between onset of illness and onset of Li treatment (years),
mean (S.D.) [range]
N.A. 14.42 (8.15)
[0.0–33.5]
N.A. N.A.
Antidepressants at the time of scanning, n (%) 7 (36.84) 12 (32.43) 0.11; 1 0.74
Antidepressants: treatment duration at the time of scanning (years),
mean (S.D.)
3.21 (3.19) 3.61 (3.42) −0.25; 17 0.8
Antipsychotics at the time of scanning, n (%) 7 (36.84) 4 (10.81) 5.39; 1 0.02
Antipsychotics: treatment duration at the time of scanning (years),
mean (S.D.)
6.44 (8.90) 3.30 (1.55) 0.69; 9 0.51
Anticonvulsants at the time of scanning, n (%) 10 (52.63) 7 (18.92) 6.75; 1 0.009
Anticonvulsants: treatment duration at the time of scanning (years),
mean (S.D.)
4.76 (3.54) 6.40 (5.16) 0.78; 15 0.45
Number of psychotropic medications (excluding benzodiazepines),
mean (S.D.)
1.26 (0.73) 1.62 (0.64) −1.89; 54 0.06
Episodes of BD on the latest mood stabilizer, n (%) 8 (50.00) 25 (67.57) 1.46; 1 0.22
BD type I diagnosis, n (%) 12 (63.16) 25 (67.57) 0.11; 1 0.74
Li, Lithium; df, degrees of freedom; BD, bipolar disorder; S.D., standard deviation; N.A., not applicable.
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response accelerates the short-term effects of Li on
brain morphology, but long-term exposure to Li affects
brain structure regardless of clinical response. This
possibility is supported by a pharmacoepidemiological
study in which only multiple prescriptions, but not a
single prescription, of Li lowered the risk of neurode-
generative disorders in patients with BD (Kessing
et al. 2008, 2010).
Our findings suggesting that the effects of Li on
hippocampal volumes are independent of long-term
treatment response are in keeping with pre-clinical
studies, in which Li prevented neuronal damage in a
range of neurotoxic models, including those unrelated
to BD (Lauterbach & Mendez, 2011). If the effects of Li
on brain structure were simply secondary to its ability
to control episodes of BD, they would be restricted to
those with mood disorders and should not generalize
to other conditions, such as Alzheimer's dementia
(AD). Epidemiological studies have shown that Li
reduces the generally elevated risk of neurodegenera-
tive disorders among patients with BD (Kessing et al.
2008, 2010; da Silva et al. 2013), which could still be
related to prevention of episodes of BD. Although
there are some promising results (Leyhe et al. 2009), Li
may not successfully treat fully symptomatic AD
(Macdonald et al. 2008; Hampel et al. 2009). It may be
more effective in pre-symptomatic stages of the illness,
where the neuropathological changes are less well pro-
nounced. In keeping with the direct biochemical effects,
Li-treated subjects with amnesticmild cognitive impair-
ment without BD were cognitively more stable over
time (Forlenza et al. 2011). Even more importantly, Li
exerted a disease-modifying effect by reducing the
levels of CSF biomarkers related to the pathophysiology
of AD (Forlenza et al. 2011). Our study provides an
additional proof of concept for further testing of Li in
neurodegenerative disorders.
The hippocampal volumes among Li-treated
patients in this study were comparable to controls,
and not larger as reported in a previous meta-analysis
(Hajek et al. 2012c). There are two possible expla-
nations for this discrepancy. First, the effects of Li on
GM may be non-linear (Yucel et al. 2007). We did not
find any correlations between the duration of Li treat-
ment and hippocampal volumes. However, because all
participants in this study had at least 2 years of Li
treatment, this truncated distribution makes the inves-
tigation of the trajectory of Li-related changes difficult.
Second, the discrepancy may be related to differences
in duration of illness and Li treatment between this
study and the meta-analysis (Hajek et al. 2012c).
Participants included in the meta-analysis had a mark-
edly shorter duration of illness and Li treatment
(weeks to years) than subjects in the current study
(years to decades).
The non-Li group in our study showed smaller hip-
pocampal volumes despite treatment with other mood
stabilizers (anticonvulsants, atypical antipsychotics),
with mostly pre-clinical evidence for neuroprotective
effects (Zarate et al. 2006). In keeping with our results,
previous studies, including prospective randomized
comparisons (Lyoo et al. 2010), also showed greater
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Fig. 2. Total hippocampal volumes adjusted for total
gray matter volume in participants divided based
on response to long-term lithium (Li) treatment
(mean±standard deviation). * p<0.05 in comparison
to the other groups.
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Fig. 1. Left and right hippocampal volumes adjusted for
total gray matter volume in lithium (Li), non-Li and control
groups (mean±standard deviation). * p<0.05 in comparison
with Li and the healthy control groups.
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effects of Li than of other mood stabilizers on hippo-
campal volumes (Beyer et al. 2004; Yucel et al. 2008;
Germana et al. 2010; Hajek et al. 2012b) or neuronal
density (Silverstone et al. 2003; Gallelli et al. 2005;
Garcia et al. 2009; Hajek et al. 2012a). The effects of
anticonvulsants or antipsychotics on brain structure
in human subjects remain controversial, with some
investigations suggesting positive effects (Garver
et al. 2005; Molina et al. 2005; Atmaca et al. 2007;
Stip et al. 2009), but the majority of studies reporting
no or negative effects of these medications on the
brain (Khorram et al. 2006; Ebdrup et al. 2011; Tariot
et al. 2011; for reviews see Moncrieff & Leo, 2010;
Leung et al. 2011). In light of these studies, we need
to consider the possibility that the GM changes in
the non-Li group were related to a greater exposure
to antipsychotics or anticonvulsants. This is perhaps
less likely because, in our study, several Li-treated
patients were also exposed to anticonvulsants (18.9%)
and antipsychotics (10.8%). More importantly, when
we excluded patients treated with anticonvulsants
or antipsychotics from both the Li and non-Li groups,
there continued to be the same pattern of significant
differences, with the smallest hippocampal volumes
among the non-Li participants. This further supports
the strength of the association, as it was confirmed
in different subsamples of patients and remained sig-
nificant despite a reduction in sample size.
Of note, although the non-Li participants showed
smaller hippocampal volumes than the controls or
the Li-treated BD patients, they were euthymic at the
time of scanning, with an average of 4.5 years since
the last episode. Previous studies have also reported
lower hippocampal volumes in groups containing
euthymic BD patients (Bearden et al. 2008; Foland
et al. 2008). Also similar to our result, Lyoo et al.
(2010) showed that valproate-treated BD patients
improved clinically in the absence of GM increases
following treatment. These findings may suggest that
the normalization of brain structural changes by medi-
cations may not be necessary to achieve euthymia or
mood stabilization.
This study has some limitations. Measuring hip-
pocampal volumes prospectively would have better
allowed us to establish the causality of the association
between Li exposure and hippocampal volumes. Con-
sidering the extensive duration of Li exposure (average
of 10.8 years), a prospective or randomized design
would not have been feasible. Although we did not
use randomization, the strict inclusion and exclusion
criteria ensured that the groups were comparable
in relevant variables known to affect hippocampal
volumes. Use of other medications possibly affecting
brain structure was allowed in both treatment groups.
Exclusion of participants treated with antipsychotics or
anticonvulsants did not change the results. The inves-
tigation of the long-term effects of Li on brain structure
and their interplay with long-term clinical response
required selected and relatively homogeneous samples
of patients who were compliant with long-term treat-
ment and did not have co-morbid conditions, which
could have confounded the results. It is not known
whether these findings would generalize to more
heterogeneous samples, such as those with substance
abuse or other co-morbid conditions, patients treated
with more than two psychotropic medications or
those with a history of multiple courses of ECT. We
did not investigate the association between the poten-
tial neuroprotective effects of Li and any other clinical
outcomes beyond the long-term treatment response.
We do not know to what extent the above-mentioned
effects on brain structure relate to the antisuicidal
properties of Li (Baldessarini et al. 2006), which also
seem to be independent of the long-term, prophylactic
response (Ahrens & Muller-Oerlinghausen, 2001).
A common limitation of structural MRI studies is
that this technology does not allow us to distinguish
whether volumetric alterations are related to changes
in size or numbers of neuronal bodies, dendrites or
glia, or even changes in vasculature, perfusion or shifts
in water content, or whether these changes are an
artifact caused by shortening of the GM T1 relaxation
times by Li (Cousins et al. 2013). General shortening
of T1 relaxation times or shifts in water content
would not explain the absence of global volumetric
changes in the presence of regionally constrained
variations in GM. In addition, the effects of Li on
MRI signals would predominantly affect morpho-
metric methods, which depend on tissue type seg-
mentation, such as VBM (Cousins et al. 2013), but
less so those involving the manual tracing methods
used here. Furthermore, a recent pre-clinical study
demonstrated that male rats treated for 8 weeks with
clinically relevant concentrations of Li showed an
increase in whole-brain volume measured by manual
segmentation of T2-weighted MR images (Vernon
et al. 2012). This effect was maintained 8 weeks after
the drug withdrawal, when Li could no longer affect
the MRI signal.
Although this was a multicenter study, with some
differences in scanner types between the sites, the pat-
tern of changes, with smallest hippocampal volumes
among non-Li patients, was preserved in all sites. In
addition, all three methods of statistically addressing
potential differences between sites yielded results com-
parable to our primary analysis, thus suggesting that
any scanner differences did not affect the findings.
The current study provides several key benefits.
With 106 participants, this is one of the largest studies
of hippocampal volumes in BD patients. The study
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was a priori designed to test the effects of Li on brain
structure. We used stringent criteria for both exposure
and absence of exposure to Li. By controlling for life-
time treatment with Li, we minimized any carry-over
effect of past history of Li exposure on GM volumes
(Atmaca et al. 2007). We used inclusion criteria to maxi-
mize the effect of illness on the brain and to minimize
differences between the Li-exposed and non-exposed
BD patients in relevant variables affecting brain
structure. Because of the strict inclusion criteria, the
participants in our study had the greatest illness
burden (average of 25.8 years and eight episodes)
and the longest duration of Li exposure (average of
10.8 years) reported in any neuroimaging study inves-
tigating the effects of Li. It is notable that the positive
effects of Li on brain structure were still evident in
patients with an average of 25 years of highly recurrent
illness (eight episodes on average). It is also of interest
that the non-Li group had smaller hippocampal
volumes even after an average of 4.5 years since the
last episode of BD. The detailed clinical information
allowed us to address important knowledge gaps
regarding the interplay between the long-term,
prophylactic treatment response and effects of Li on
brain structure.
To conclude, in support of the neuroprotective
effects of Li, the Li-treated BD patients had hippo-
campal volumes comparable to controls and larger
than the non-Li group, with comparable numbers of
episodes or cumulative time spent in episodes. These
effects of Li did not seem to be related to clinical
heterogeneity and were still evident in patients with
an average of 25 years of highly recurrent illness.
Furthermore, the association between Li treatment
and hippocampal volume was independent of long-
term treatment response and occurred even in parti-
cipants with episodes of BD while on Li. These results
raise the possibility that the effects of Li on hippo-
campal volumes may generalize to patients with
neuropsychiatric illnesses other than BD.
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